Jeremy Skillington of Poolbeg: exclusive agreement with University College Dublin for a late preclinical stage vaccine candidate for Melioidosis
Episode 906, Sep 21, 2022, 06:26 AM
Jeremy Skillington, CEO of Poolbeg Pharma #POLB outlines the exclusive Licence Agreement with University College Dublin for a late preclinical stage vaccine candidate for Melioidosis, a disease for which there is no currently approved vaccine available.
Jeremy Skillington, CEO of Poolbeg Pharma #POLB outlines the exclusive Licence Agreement with University College Dublin for a late preclinical stage vaccine candidate for Melioidosis, a disease for which there is no currently approved vaccine available.
Highlights
The vaccine candidate, which is being developed by Poolbeg as POLB 003, was invented following many years of research by Associate Professor Siobhán McClean, UCD School of Biomolecular and Biomedical Science, and was a recipient of a Wellcome Trust Award to aid its development.
To read the full RNS click here
Highlights
The vaccine candidate, which is being developed by Poolbeg as POLB 003, was invented following many years of research by Associate Professor Siobhán McClean, UCD School of Biomolecular and Biomedical Science, and was a recipient of a Wellcome Trust Award to aid its development.
To read the full RNS click here